{"pub": "reuters", "url": "https://uk.reuters.com/article/uk-gsk-heartburn-zantac/gsk-recalls-popular-heartburn-medicine-zantac-u-k-medicines-watchdog-idUKKBN1WN1SF", "downloaded_at": "2019-10-08 15:51:35.058546+00:00", "title": "GSK recalls popular heartburn medicine Zantac : U.K. medicines watchdog", "language": "en", "text": "FILE PHOTO: The GlaxoSmithKline (GSK) logo is seen on top of GSK Asia House in Singapore, March 21, 2018. REUTERS/Loriene Perera\n\n(Reuters) - GlaxoSmithKline Plc is recalling its heartburn medicine Zantac as a \u201cprecautionary measure\u201d due to a probable cancer-causing impurity in the drug, Britain\u2019s medicines watchdog said on Tuesday.\n\nGSK is recalling all unexpired stock of Zantac, also sold generically as ranitidine, from pharmacies as a precaution due to possible contamination with an impurity NDMA, which has genotoxic and carcinogenic potential, the Medicines and Healthcare products Regulatory Agency (MHRA) said.", "description": "GlaxoSmithKline Plc is recalling its heartburn medicine Zantac as a \"precautionary measure\" due to a probable cancer-causing impurity in the drug, Britain's medicines watchdog said on Tuesday.", "authors": ["Reuters Editorial", "Min Read"], "top_image": "https://s3.reutersmedia.net/resources/r/?m=02&d=20191008&t=2&i=1438489241&w=1200&r=LYNXMPEF9716M", "published_at": "2019-10-08"}